RU2017136423A3 - - Google Patents

Download PDF

Info

Publication number
RU2017136423A3
RU2017136423A3 RU2017136423A RU2017136423A RU2017136423A3 RU 2017136423 A3 RU2017136423 A3 RU 2017136423A3 RU 2017136423 A RU2017136423 A RU 2017136423A RU 2017136423 A RU2017136423 A RU 2017136423A RU 2017136423 A3 RU2017136423 A3 RU 2017136423A3
Authority
RU
Russia
Application number
RU2017136423A
Other languages
Russian (ru)
Other versions
RU2734774C2 (ru
RU2017136423A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017136423A publication Critical patent/RU2017136423A/ru
Publication of RU2017136423A3 publication Critical patent/RU2017136423A3/ru
Application granted granted Critical
Publication of RU2734774C2 publication Critical patent/RU2734774C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
RU2017136423A 2015-04-16 2016-04-18 Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном RU2734774C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (3)

Publication Number Publication Date
RU2017136423A RU2017136423A (ru) 2019-05-16
RU2017136423A3 true RU2017136423A3 (https=) 2019-09-04
RU2734774C2 RU2734774C2 (ru) 2020-10-23

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017136423A RU2734774C2 (ru) 2015-04-16 2016-04-18 Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном

Country Status (14)

Country Link
US (2) US20160303056A1 (https=)
EP (2) EP3283073A4 (https=)
JP (2) JP2018511625A (https=)
KR (1) KR20180002677A (https=)
CN (1) CN107613979A (https=)
AU (1) AU2016248443B2 (https=)
BR (1) BR112017022244A2 (https=)
CA (2) CA2982875C (https=)
HK (1) HK1249858A1 (https=)
IL (1) IL255026A0 (https=)
MX (1) MX2017013133A (https=)
RU (1) RU2734774C2 (https=)
WO (1) WO2016168802A2 (https=)
ZA (1) ZA201707710B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023748A2 (pt) 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CA3134756A1 (en) 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
EP4164407A4 (en) * 2020-06-14 2024-08-28 L-Nutra Inc. BAR/DRINK FOR INTERMITTENT FASTING THAT MAINTAINS AND PROLONGS THE FASTING STATE
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
CN103347521B (zh) * 2010-12-06 2018-05-25 全球癌症治疗有限责任公司 用于治疗癌症的使用化疗和免疫治疗的代谢靶向癌细胞的方法
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
WO2015134837A2 (en) * 2014-03-06 2015-09-11 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Also Published As

Publication number Publication date
RU2734774C2 (ru) 2020-10-23
CN107613979A (zh) 2018-01-19
KR20180002677A (ko) 2018-01-08
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
EP3283073A2 (en) 2018-02-21
JP2018511625A (ja) 2018-04-26
ZA201707710B (en) 2019-04-24
EP4299061A2 (en) 2024-01-03
CA2982875C (en) 2021-10-19
JP2021008491A (ja) 2021-01-28
EP4299061A3 (en) 2024-02-28
HK1249858A1 (zh) 2018-11-16
EP3283073A4 (en) 2019-02-13
IL255026A0 (en) 2017-12-31
BR112017022244A2 (pt) 2018-07-10
AU2016248443B2 (en) 2021-03-18
US20210137856A1 (en) 2021-05-13
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07
AU2016248443A1 (en) 2017-11-02
RU2017136423A (ru) 2019-05-16
CA2982875A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
BR112017027922A2 (https=)
RU2017136423A3 (https=)
BE2015C047I2 (https=)
BR0000126B1 (https=)
BR0000695B1 (https=)
BR0000763F1 (https=)
BR0001536B1 (https=)
BR0001684B1 (https=)
BR0001810B1 (https=)
BR0002033B1 (https=)
BR0002402B1 (https=)
BR0002435B1 (https=)
BR0002694B1 (https=)
BR0002802B1 (https=)
BR0002874B1 (https=)
BR0003166B1 (https=)
BR0003189B1 (https=)
BR0003208B1 (https=)
BR0003401B1 (https=)
BR0003686B1 (https=)
BR0003746B1 (https=)
BR0003751B1 (https=)
BR0003928B1 (https=)
BR0004687B1 (https=)
BR0005041B1 (https=)